New oxygen system a 'game changer' for battlefield
A new portable oxygen delivery system has been developed to improve casualty survival rates for soldiers and civilians.
The system, which was developed by the Wiltshire-based Defence Science and Technology Laboratory (DSTL) and the Defence Medical Service (DMS), weighs just 5kg (11lb) and is able to offer sustained oxygen supply in a safer and easier form than conventional gas cylinders.
"The ability to deliver oxygen at the point of injury represents a game-changing advance in battlefield medicine," said Major Andrew Maggs, DSTL military advisor.
The system works by taking air from the environment and removing nitrogen to leave a breathable oxygen-rich gas that can be delivered to patients.
Oxygen therapy is critical for trauma patients suffering from blood loss, head injuries and lung trauma.
By getting oxygen delivery directly to the point of injury, the system can dramatically improve the likelihood of survival and recovery.
"By reducing logistical burden and improving safety, the system will provide critical care in situations where every second counts," Major Maggs explained.
Dr Paul Hollinshead, DSTL chief executive, added: "In operational terms, this system will reduce the logistical strain on supply chains while improving battlefield care.
"The ability to also reuse the system with external power or replaceable batteries means it offers unparalleled flexibility."
It is not yet known when the system will be first used, but 15 prototypes will soon be ready to deploy.
DSTL is also working on a mass-producible version that can withstand rigorous military use.
The system currently costs £15,000 per unit but it is hoped a more cost effective version can be designed.
Follow BBC Wiltshire on Facebook, X and Instagram. Send your story ideas to us on email or via WhatsApp on 0800 313 4630.
Military families speak out on mouldy homes
Thousands of UK gas masks being sent to Ukraine
Statue displays warn of military land dangers
DSTL
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
6 hours ago
- Business Insider
AstraZeneca announces results from MATTERHORN Phase III trial of IMFINZI
Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca's (AZN) IMFINZI in combination with standard-of-care FLOT chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival, EFS, versus chemotherapy alone. Patients were treated with neoadjuvant IMFINZI in combination with chemotherapy before surgery, followed by adjuvant IMFINZI in combination with chemotherapy, then IMFINZI monotherapy. The trial evaluated this regimen versus perioperative chemotherapy alone for patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction, GEJ, cancers. In a planned interim analysis, patients treated with the IMFINZI-based perioperative regimen showed a 29% reduction in the risk of disease progression, recurrence or death versus chemotherapy alone. Estimated median EFS was not yet reached for the IMFINZI arm versus 32.8 months for the comparator arm. For the secondary endpoint of overall survival, a strong trend was observed in favor of the IMFINZI-based perioperative regimen. The trial will continue to follow OS, which will be formally assessed at the final analysis. Confident Investing Starts Here:
Business Insider
6 hours ago
- Business Insider
Guardant Health presented results of largest study on ctDNA in colon cancer
Guardant Health (GH) presented results of the largest study to date evaluating circulating tumor DNA, ctDNA, in colon cancer prior to chemotherapy, demonstrating the ability of the Guardant Reveal test to stratify the risk of disease recurrence and overall survival, and thus inform treatment decisions after surgery. Data from the phase III trial of FOLFOX-based adjuvant chemotherapy involving over 2,000 patients with stage III colon cancer with median follow-up of 6.1 years were presented at the 2025 American Society for Clinical Oncology Annual Meeting. Results demonstrated that circulating tumor DNA detected in the bloodstream after cancer surgery and prior to the start of adjuvant therapy, using the Guardant Reveal test, is a strong predictor of the risk of disease recurrence and poorer survival, and suggest the potential for ctDNA testing to improve decision-making at a critical time point for post-operative chemotherapy. Specifically: Among patients with post-surgical ctDNA detected, 62.6% had the cancer return within 3 years, despite having had adjuvant chemotherapy, while only 15.4% of patients with undetectable ctDNA recurred in the same period. The level of ctDNA, or tumor fraction, showed promise in identifying individuals who are less likely to clear residual disease with adjuvant treatment.
Yahoo
8 hours ago
- Yahoo
Two people rescued from small plane crash in Long Island Sound
June 1 (UPI) -- Crews rescued two people aboard a small plane that crashed into Long Island Sound Sunday near a Connecticut airport, according to the FAA and U.S. Coast Guard. The Piper PA-32 plane went down about 10:30 a.m. south of the Tweed New Haven Airport in New Haven, a statement from the FAA said. "The two persons onboard the aircraft were rescued and in stable condition," the Coast Guard said in a statement, according to ABC News. The Coast Guard dispatched a 45-foot New Haven-based rescue boat to the scene after the Sector Long Island Sound Command Center received notification of the incident from the air traffic control tower that the plane had gone down near the Thimble Islands close to Branford, Ct. The rescued passengers were taken to the Stony Creek Pier in Branford, the Coast Guard said. The FAA is investigating the incident.
